
Testosterone challenges reshape the hormone-cancer conversation
678. Low Hormones and Cancer: What You’re Not Being Told
The episode examines how low testosterone is interpreted in women and men, while separating supervised replacement therapy from unsupervised steroid use amid cancer concerns.
- 1Testosterone may influence women’s mood, cognition, energy, and long-term health, yet deficiency can be overlooked in routine care.
- 2DHEA is not equivalent to prescribed testosterone, and supplement quality, dosing, and androgenic side effects complicate self-treatment.
- 3Breast and prostate cancer decisions require individualized clinical context rather than automatic assumptions about testosterone or estrogen therapy.
Don't miss
Terri DeNeui draws a firm line between replacing deficient testosterone under medical supervision and using anabolic steroids, while warning against unsupervised online treatment.
The brief
Terri DeNeui joins Amie Hornaman to argue that testosterone can matter to women’s mood, cognition, energy, and long-term health—not only to men.
The conversation distinguishes testosterone from DHEA and questions whether standard lab ranges reflect healthy function, especially when results are labeled normal despite persistent symptoms.
Cancer concerns drive the sharpest debate: breast and prostate risks, estrogen evidence, PSA, and receptor biology all demand more context than blanket rules provide.
DeNeui also separates medically supervised replacement from anabolic steroid use, warning that online hormones and self-directed DHEA can create avoidable risks.
The episode’s central challenge is to treat hormone decisions as individualized clinical questions rather than conclusions dictated by gender, a single lab result, or fear.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.
